It was a pleasure to meet with Sabrina Paganoni (Harvard Medical School, Boston, MA, USA) to discuss the CENTAUR study findings, and where AMX0035 is likely to be placed in the treatment paradigm for amyotrophic lateral sclerosis (ALS).
The abstract entitled: ‘Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- Could you tell us a little about the CENTAUR study and its findings? (0:06)
- What has the recent analysis taught us about the long term efficacy and safety of AMX0035? (1:31)
- Where is AMX0035 likely to be placed in the treatment paradigm for ALS? (2:18)
Disclosures: Sabrina Paganoni reports research grants from Amylyx Therapeutics, Revalesio Corporation, Ra Pharma, Biohaven, Clene, Prilenia, The ALS Association, the American Academy of Neurology, ALS Finding a Cure, the Salah Foundation, the Spastic Paraplegia Foundation, the Muscular Dystrophy Association; and reports personal consulting fees for advisory panels from Orion.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Neuromuscular Diseases
Renato Mantegazza, EAN 2021: Phase 3 ADAPT Study Results
touchNEUROLOGY met with Renato Mantegazza (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy), to discuss the phase 3 ADAPT study results investigating efgartigimod for the treatment of myasthenia gravis. The abstract entitled: ‘Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results’ was […]
Renato Mantegazza, EAN 2021: Challenges in the Treatment of Myasthenia Gravis
touchNEUROLOGY met with Renato Mantegazza (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy) to discuss the challenges that arise in treating patients with myasthenia gravis. The abstract entitled: ‘Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results’ was presented at the 7th […]
Jeffrey Guptill, AAN 2021: Vivacity-MG Study Results
We were delighted to meet with Jeffery Guptill (Duke University Medical Center, Durham, NC, USA) to discuss the Vivacity-MG study results (NCT03772587), investigating nipocalimab as a treatment option for Myasthenia Gravis. The abstract entitled: ‘Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!